mySugr GmbH
mySugr is a digital health company that provides a diabetes management app and tools to simplify daily diabetes routines for people with diabetes.
Classification
Profile
Funding
A diabetes management app that simplifies daily routines and reduces complexity for people with diabetes, aiming to make the condition 'suck less'.
Individuals living with diabetes who seek tools to monitor and manage their condition, supported by the confidence-building ethos of the brand.
freemium, enterprise licensing, insurance partnerships
Direct-to-consumer via app distribution, with specific integrations like the Accu-Chek SmartGuide CGM available in selected markets.
Roche family (parent company) and device manufacturers like Accu-Chek for CGM integration, leveraging the Roche network for trust and distribution.
R&D for app development and integration, platform maintenance, and marketing to support the 'made by people with diabetes' community-driven approach.
The mySugr digital platform, proprietary diabetes management tools, and the trust/brand equity derived from being part of the Roche family.
Developing and maintaining the diabetes management app, integrating with medical devices like CGMs, and providing know-how and confidence-building resources.
Community-driven and self-serve, emphasizing empathy ('made by people with diabetes') and providing tools that simplify daily management to retain users.
Competes in the digital diabetes management space; differentiates through its empathetic brand voice, Roche backing, and seamless integration with Accu-Chek devices.
The high complexity of daily diabetes routines and the emotional burden of managing the condition, which the app aims to simplify and alleviate.
- Introduce Tiered Enterprise Packages
Geographic focus: Are you interested in expanding the BMC to specific regions (e.g., US vs. EU) where reimbursement models differ? · Product roadmap: Do you have plans to add a tele-consultation layer or integrate with Roche’s insulin-pump portfolio? · Data-privacy stance: How strict are your GDPR/CCPA compliance requirements for future B2B data-li
- The freemium‑plus‑partner model is confirmed by multiple independent analyses of mySugr’s business (e.g., Research2Guidance interview [2] and AppInventiv cost study [4]).
- Roche’s acquisition in 2017 provides a solid clinical and financial backbone, reducing regulatory risk and enabling scale (Roche story [6]).
- Social‑media pain points align with broader diabetes‑community sentiment reported in recent health‑tech market surveys (e.g., European Digital Health Report [5]).
No investors recorded yet.